ORLANDO, FL / ACCESSWIRE / November 15, 2024 / RedChip Companies will air interviews with MUSQ Global Music Industry ETF (NYSE:MUSQ) and OKYO Pharma Ltd. (Nasdaq:OKYO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 16, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
In an exclusive interview, David Schulhof, Founder and CEO of MUSQ LLC, the company behind the MUSQ Global Music Industry ETF, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into how the MUSQ ETF provides investors with exposure to the global music ecosystem. Tracking the MUSQ Global Music Industry Index (MUSQIX), the ETF includes publicly traded companies with core interests in music streaming, content and distribution, live events, satellite and broadcast radio, and music equipment and technology. The global music industry is projected to grow at a double-digit pace, with Goldman Sachs predicting the industry's revenue will reach $163.7 billion by 2030.
Gary S. Jacob, PhD, CEO of OKYO Pharma, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's progress in developing treatments for neuropathic corneal pain and dry eye disease. He highlights the recent initiation of a Phase 2 clinical trial for OK-101, a topical ocular treatment designed to address neuropathic corneal pain (NCP), a debilitating condition currently lacking an FDA-approved treatment. OK-101 is a novel, non-opioid therapeutic aimed at alleviating severe and debilitating pain associated with corneal nerve damage. OKYO announced on October 16, 2024 the opening of this trial of OK-101 to treat NCP in patients with this debilitating condition. The trial is being conducted at Tufts Medical Center, focusing on evaluating OK-101's effectiveness in managing neuropathic corneal pain resulting from various sources, including dry eye disease, surgery, or infections.
MUSQ and OKYO Pharma are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About MUSQ LLC
MUSQ LLC is the mastermind behind the MUSQ Global Music Industry Index (MUSQIX), and the MUSQ Global Music Industry ETF (NYSE:MUSQ). MUSQ LLC's founder and CEO, David Schulhof, is an experienced music investor and operator with more than 25 years of investing and operating public and private companies in the music and entertainment industry.
For more information, please contact [email protected]
*For a complete list of MUSQ holdings and sector breakdown, please click here. Holdings subject to change.
** Source: Yang, Lisa, et al, Music in the Air, Goldman Sachs Equity Research, May 01, 2024
MUSQ Global Music Industry ETF is offered by prospectus. Carefully consider the investment objectives, risks, charges, and expenses. This and other important information can be found in the MUSQ ETF prospectus, which should be read carefully before investing and can be obtained by visiting https://musqetf.com or by calling 1-855- MUSQ-ETF(687-7383).
Risk Disclosures
There is no guarantee the Fund will achieve its stated objectives. In addition to the normal risks associated with investing, international investments may involve the risk of capital loss from unfavorable fluctuation in currency values, differences in generally accepted accounting principles or social, economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. In addition to the normal risks associated with investing, investments in small- or mid-capitalization companies typically exhibit higher volatility. The Fund's concentration in an industry or sector can increase the impact of, and potential losses associated with, the risks from investing in those industries/sectors. The Fund is non-diversified.
The Fund is new and has a limited operating history for investors to evaluate. A new and smaller fund may not attract sufficient assets to achieve investment and trading efficiencies. The Fund may invest in securities denominated in foreign currencies. Because the Fund's NAV is determined in U.S. dollars, the Fund's NAV could decline if currencies of the underlying securities depreciate against the U.S. dollar or if there are delays or limits on repatriation of such currencies. Currency exchange rates can be very volatile and can change quickly and unpredictably. All investing involves risk, and asset allocation and diversification do not guarantee a profit or protection against a loss. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, might be worth more or less than their original cost. ETFs are subject to risks similar to those of stocks, as well as other risks specific to the particular ETF. ETF shares are traded on exchanges, and are traded and priced throughout the trading day. ETFs permit an investor to purchase a selling interest in a portfolio of stocks throughout the trading day. Because ETFs trade on an exchange, ETF shares are bought and sold at market price (not NAV). The prices of ETFs may sometimes vary significantly from the NAVs of a ETFs' underlying securities. Brokerage commissions will reduce returns.
Exchange Traded Concepts, LLC serves as the investment advisor. The Funds are distributed by SEI Investments Distribution Co., which is not affiliated with Exchange Traded Concepts, LLC or any of its affiliates.
About OKYO
OKYO Pharma Limited (NASDAQ:OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of NCP and DED, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to address ocular pain and inflammation. OKYO recently announced on October 16, 2024 the opening of a Phase 2 trial of OK-101 to treat NCP in patients with this debilitating condition. In addition, the Company recently completed a Phase 2 DED trial of OK-101 which demonstrated statistical significance in reduction of ocular pain. For further information, please visit www.okyopharma.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
[email protected]
--END--
SOURCE: RedChip